ROCHE HLDGS AG (RHHBY)

27.91
0.17 0.63
OTC
Prev Close 27.73
Open 27.94
Day Low/High 27.83 / 28.02
52 Wk Low/High 27.65 / 36.82
Volume 635.31K
Exchange OTC
Shares Outstanding 5620.50B
Market Cap 156.64B
Div & Yield N.A. (N.A)

Latest News

Roche Launches VENTANA DP 200 Slide Scanner For Digital Pathology

Roche Launches VENTANA DP 200 Slide Scanner For Digital Pathology

- Image quality and ease of use set new standard for digital pathology, with the goal of empowering faster, better care for patients

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Carboplatin And Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Phase III IMpower150 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Plus Carboplatin And Paclitaxel Helped People With Advanced Lung Cancer Live Longer Compared To Avastin Plus Carboplatin And Paclitaxel

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower150 study met its co-primary endpoint of overall survival (OS) at this interim analysis and showed that initial...

FDA Approves Genentech's Lucentis (ranibizumab Injection) 0.3 Mg Prefilled Syringe For Diabetic Macular Edema And Diabetic Retinopathy

FDA Approves Genentech's Lucentis (ranibizumab Injection) 0.3 Mg Prefilled Syringe For Diabetic Macular Edema And Diabetic Retinopathy

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Squamous Lung Cancer

Phase III IMpower131 Study Showed Genentech's TECENTRIQ (Atezolizumab) Plus Chemotherapy (Carboplatin And ABRAXANE) Reduced The Risk Of Disease Worsening Or Death In The Initial Treatment Of People With A Type Of Advanced Squamous Lung Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMpower131 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination...

Roche Launches The New Cobas M 511 Analyzer, Signaling A New Era In Hematology Testing

Roche Launches The New Cobas M 511 Analyzer, Signaling A New Era In Hematology Testing

Clinicians to benefit from integrated workflow and faster access to abnormal results

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Mylan Shares Surge as Analyst Says It's Poised to Gain Share From Rivals

Morgan Stanley analyst David Risinger is upbeat about the drugmaker's generic drug growth prospects in the U.S.

Roche Achieves Two Major Milestones In The Evolution Of Decision Support Platform

Roche Achieves Two Major Milestones In The Evolution Of Decision Support Platform

-- HITRUST CSF® certification granted for NAVIFY™ Tumor Board solution

Shionogi's Single-Dose Flu Drug Gets Japanese Approval

Shionogi's Single-Dose Flu Drug Gets Japanese Approval

The drug likely wouldn't be approved in the U.S. before 2019, however.

FDA Grants Priority Review For Genentech's Rituxan (Rituximab) For Pemphigus Vulgaris

FDA Grants Priority Review For Genentech's Rituxan (Rituximab) For Pemphigus Vulgaris

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.

Roche Receives FDA Clearance For Factor II And Factor V Test On The Cobas® 4800 System

Roche Receives FDA Clearance For Factor II And Factor V Test On The Cobas® 4800 System

- Provides a rapid workflow to aid in the diagnosis of patients with suspected thrombophilia

Roche Diagnostics Recognizes Wisconsin Diagnostic Laboratories As Roche Molecular Center Of Excellence

Roche Diagnostics Recognizes Wisconsin Diagnostic Laboratories As Roche Molecular Center Of Excellence

Institution joins strategic network designed to help accelerate advancement of new methods in molecular diagnostics, anatomic pathology and sequencing

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Phase II Data Support Potential For Novel Anti-VEGF/Anti-Angiopoietin-2 Bispecific Antibody, RG7716, For People With Diabetic Macular Edema

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced encouraging results from the Phase II BOULEVARD study.

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death By 26 Percent In Certain People With Advanced Kidney Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced results from the positive Phase III IMmotion151 study of TECENTRIQ ® (atezolizumab) and Avastin ® (bevacizumab) as a first-line...

Wall Street Futures Edge Higher Amid 'Super Thursday' Earnings; Apple Q1 Awaits

Wall Street Futures Edge Higher Amid 'Super Thursday' Earnings; Apple Q1 Awaits

Wall Street futures are edging higher amid a "Super Thursday" of corporate earnings that will culminate with Apple's much-anticipated quarterly update and the first official indication on sales of its flagship iPhone X.

Roche Launches CE-marked VENTANA MMR IHC Panel For Patients Diagnosed With Colorectal Cancer

Roche Launches CE-marked VENTANA MMR IHC Panel For Patients Diagnosed With Colorectal Cancer

-- The VENTANA MMR IHC Panel1 helps differentiate between sporadic colorectal cancer and probable Lynch syndrome, a hereditary form of colorectal cancer

Syapse Enters Strategic Collaboration With Roche To Advance Precision Medicine In Oncology

Syapse Enters Strategic Collaboration With Roche To Advance Precision Medicine In Oncology

Multi-year partnership to focus on product development and clinical delivery to bring precision medicine to more patients

GE, Roche Enter Partnership To Develop An Industry-first Digital Platform, Using Advanced Analytics To Provide Workflow Solutions And Apps That Support Clinical Decisions (Photo: Business Wire)

GE, Roche Enter Partnership To Develop An Industry-first Digital Platform, Using Advanced Analytics To Provide Workflow Solutions And Apps That Support Clinical Decisions (Photo: Business Wire)

GE Healthcare has entered into a strategic, long-term partnership with Roche (SIX: RO, ROG; OTCQX: RHHBY) to jointly develop and co-market digital clinical decision support solutions.

Best Biotech Stock Trades and Mergers to Watch in 2018

Best Biotech Stock Trades and Mergers to Watch in 2018

Here's a look at biotech stock trades, takeout targets and pot sellers that will dominate 2018.

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

Could These 2 Biotech 'Busted IPOs' Be the Next Ignyta?

After Roche's acquisition of Ignyta, I have high hopes for these other two names in 2018.

Roche And Accenture Collaborate To Enhance Digital Healthcare For Cancer Patients

Roche And Accenture Collaborate To Enhance Digital Healthcare For Cancer Patients

Data Integration Services Crucial to Decision Support in Oncology

2 Biotech 'Busted IPOs' to Watch in 2018

2 Biotech 'Busted IPOs' to Watch in 2018

Are these names the next 'Ignytas'?

Roche And Ignyta Reach Definitive Merger Agreement

Roche And Ignyta Reach Definitive Merger Agreement

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Ignyta, Inc. (NASDAQ: RXDX) today announced they have entered into a definitive merger agreement for Roche to fully acquire Ignyta at a price of US$ 27.

FDA Approves Genentech's Perjeta (pertuzumab) For Adjuvant Treatment Of Specific Type Of Early Breast Cancer

FDA Approves Genentech's Perjeta (pertuzumab) For Adjuvant Treatment Of Specific Type Of Early Breast Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.

7 Hot Investing Bets to Make in Biotech

7 Hot Investing Bets to Make in Biotech

These favorite names in the volatile sector offer the potential for high rewards.

Genentech Announces Phase III Data Showing Venclexta Plus Rituxan Reduced The Risk Of Disease Progression Or Death By 83 Percent Compared To A Standard Of Care Regimen In Previously Treated Chronic Lymphocytic Leukemia

Genentech Announces Phase III Data Showing Venclexta Plus Rituxan Reduced The Risk Of Disease Progression Or Death By 83 Percent Compared To A Standard Of Care Regimen In Previously Treated Chronic Lymphocytic Leukemia

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the first results from the pivotal Phase III MURANO study evaluating Venclexta™ (venetoclax) plus Rituxan ® (rituximab)...

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death For The Initial Treatment Of Certain People With Advanced Kidney Cancer

Phase III IMmotion151 Study Showed Genentech's TECENTRIQ (Atezolizumab) And Avastin (Bevacizumab) Reduced The Risk Of Disease Worsening Or Death For The Initial Treatment Of Certain People With Advanced Kidney Cancer

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMmotion151 study met its co-primary endpoint of investigator-assessed progression-free survival (PFS) and demonstrated...